Duke University Hospital Pediatric Pulmonology

Topics

• Cystic Fibrosis Research Advances 136
• Asthma and respiratory diseases 43
• Lysosomal Storage Disorders Research 20
• Workplace Health and Well-being 15
• Neonatal Respiratory Health Research 11
• Sinusitis and nasal conditions 11
• Amyotrophic Lateral Sclerosis Research 10
• Olfactory and Sensory Function Studies 9
• Hemoglobinopathies and Related Disorders 8
• Neuroscience of respiration and sleep 7
• Muscle Physiology and Disorders 6
• Vitamin D Research Studies 6

Most cited

1. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.

   The Lancet. Respiratory medicine · 2025 · 92 citations · Jennifer Taylor-Cousar

2. Cystic fibrosis.

   Nature reviews. Disease primers · 2024 · 168 citations · Jennifer Taylor-Cousar

3. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.

   American journal of respiratory and critical care medicine · 2021 · 251 citations · Jennifer Taylor-Cousar

4. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.

   American journal of respiratory and critical care medicine · 2023 · 128 citations · Jennifer Taylor-Cousar

5. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis.

   Lancet (London, England) · 2023 · 145 citations · Jennifer Taylor-Cousar

6. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.